Acadia Pharmaceuticals initiated with bullish view at Deutsche Bank, here’s why

Deutsche Bank analyst Neena Bitritto-Garg initiated coverage of Acadia Pharmaceuticals with a Buy rating and $25 price target. The firm expects the stable Parkinson’s disease psychosis, or PDP, base business for Nuplazid to grow modestly to about $650M in peak sales through expected loss of exclusivity in late 2030, which “sets a floor on shares,” and sees potential for near-term share price appreciation on an expected ANDA proceedings decision due around year-end, the analyst tells investors.